A huge merger may be brewing in the drug industry. Pfizer has approached British rival AstraZeneca about a takeover, according to the Sunday Times.
Excitement is starting to build over the planned American IPO of the Chinese e-commerce giant Alibaba. It could be the largest U.S. IPO ever.
After five straight quarters of strong gains, the market rode a treadmill for the past 3 months -- lots of movement, but ending up pretty much where it started.
Biotech and health care stocks looked like they needed a transfusion of market confidence Monday, as for the second session in a row, their performance was anemic.
Tensions over the Ukraine-Russian conflict remain high, but there were no new developments that blocked investors on Wall Street from buying.
Federal health experts are taking a second look this week at the heart safety of pain medications used by millions of Americans to treat arthritis and other aches and pains.
A proposed bill in one state could change future generations of smartphones that all of us buy.
The NFL has awarded a series of extra games for next season to CBS, but that means the network will have to find a temporary new home for one of its most popular sitcoms.
U.S. investors are uncertain about whether we're in the midst of a temporary retreat, or a more fundamental end to the long running bull market.
Liquor-maker Beam agrees to be acquired by Suntory Holdings of Japan for $16 billion.
GlaxoSmithKline will stop paying doctors for promoting its drugs and scrap prescription targets for its marketing staff.
CVS Caremark's third-quarter net income climbed 25 percent in a performance that beat Wall Street expectations.
Johnson & Johnson has agreed to pay a $2.2 billion penalty and plead guilty to a misdemeanor, ending federal investigations.
Leading senators are said to be this close to reaching a deal to temporarily ending the twin stalemates over the budget and debt ceiling.
Walgreen is moving 120,000 employees to a private health insurance exchange from coverage provided directly from carriers.
Johnson & Johnson is recalling 200,000 bottles of Motrin Infants Drops formula due to the risk that they contain tiny particles of plastic.
Though news of handful of corporate deals pushed stocks higher early Monday, the markets closed slightly lower after to Secretary of State Kerry boosted the pressure on Syria.
Microsoft starts the second of two landmark trials with a unit of Google over patent rights for certain smartphone and Internet technologies.
AstraZeneca takes another step to bolster its pipeline of new cancer drugs by agreeing to acquire biotech company Amplimmune for up to $500 million.
Amgen is close to buying Onyx Pharmaceuticals $125 a share, or more than $10 billion, in a deal that is expected to be announced as soon as Monday, sources say.
Medical Marijuana is now legal in 20 states, and there are some legitimate ways to invest in it. But there are also some sketchy investment schemes to watch out for.
Yum Brands and its KFC unit continue to struggle in China, as a key measure of Yum's sales tumbled 13 percent last month, far worse than expected.
Drug-giants Merck and Pfizer beat earnings estimates, as patent expirations on key drugs loom.
Pfizer reports better-than-expected earnings as the drugmaker lines up a business split that could lead to the spin-off of its generics division.
Apple files an application in Japan to get a trademark on the name "iWatch," fueling rumors that the company is getting ready to roll out a new device.
Chinese factory workers release their U.S. boss, held captive for a week, after a compensation dispute is resolved.
The equity market got off to a hot start but quickly lost its footing. All three indexes closed lower, with trading more volatile than it's been in months.